AC
Armistice Capital Portfolio holdings
AUM
$2.64B
This Quarter Return
+2.88%
1 Year Return
+0.99%
3 Year Return
+16.29%
5 Year Return
+18.04%
10 Year Return
+34.8%
AUM
$4.3B
AUM Growth
+$4.3B
(+16%)
Cap. Flow
+$407M
Cap. Flow
% of AUM
9.47%
Top 10 Holdings %
Top 10 Hldgs %
30.73%
Holding
273
New
80
Increased
91
Reduced
49
Closed
48
Top Buys
| 1 |
UnitedHealth
UNH
|
$71.8M |
| 2 |
Neurocrine Biosciences
NBIX
|
$70M |
| 3 |
Colgate-Palmolive
CL
|
$63.5M |
| 4 |
Johnson & Johnson
JNJ
|
$61.7M |
| 5 |
Dentsply Sirona
XRAY
|
$55.8M |
Top Sells
| 1 |
Pacira BioSciences
PCRX
|
$73.1M |
| 2 |
Freshpet
FRPT
|
$62.8M |
| 3 |
PARA
Paramount Global Class B
PARA
|
$49.9M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
$47.7M |
| 5 |
AB InBev
BUD
|
$29.9M |
Sector Composition
| 1 | Healthcare | 70.36% |
| 2 | Consumer Staples | 8.49% |
| 3 | Consumer Discretionary | 7.88% |
| 4 | Technology | 7.45% |
| 5 | Communication Services | 3.38% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Neurocrine Biosciences
NBIX
$13.8B
| $161M | 2.32% | 1,592,000 +692,000 | +77% | +$70M |
|
2
Travere Therapeutics
TVTX
$1.56B
| $161M | 2.31% | 7,148,000 +736,000 | +11% | +$16.6M |
|
3
Supernus Pharmaceuticals
SUPN
$2.53B
| $158M | 2.27% | 4,350,000 -6,000 | -0.1% | -$217K |
|
4
PTC Therapeutics
PTCT
$3.92B
| $142M | 2.04% | 2,924,000 -472,000 | -14% | -$22.9M |
|
|
MRTX
5
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $137M | 1.98% | 3,692,000 +204,000 | +6% | +$7.58M |
|
6
Incyte
INCY
$16.5B
| $135M | 1.95% | 1,872,000 +460,000 | +33% | +$33.2M |
|
7
Biogen
BIIB
$19.4B
| $125M | 1.8% | 450,000 +50,000 | +13% | +$13.9M |
|
8
GSK
GSK
$79.9B
| $115M | 1.66% | 3,236,000 +180,000 | +6% | +$6.4M |
|
9
Amazon
AMZN
$2.44T
| $95.4M | 1.37% | 924,000 -240,000 | -21% | -$24.8M |
|
10
Exact Sciences
EXAS
$8.98B
| $92M | 1.32% | 1,356,000 -180,000 | -12% | -$12.2M |
|
|
11
UnitedHealth
UNH
$281B
| $90.7M | 1.31% | 192,000 +152,000 | +380% | +$71.8M |
|
|
12
Dentsply Sirona
XRAY
$2.85B
| $88.6M | 1.28% | 2,256,000 +1,420,000 | +170% | +$55.8M |
|
13
argenx
ARGX
$43.6B
| $83.5M | 1.2% | 224,000 +54,000 | +32% | +$20.1M |
|
14
Alphabet (Google) Class A
GOOGL
$2.57T
| $83M | 1.19% | 800,000 -176,000 | -18% | -$18.3M |
|
15
Enanta Pharmaceuticals
ENTA
$180M
| $81.4M | 1.17% | 2,012,000 -66,000 | -3% | -$2.67M |
|
16
Agios Pharmaceuticals
AGIO
$2.19B
| $79.5M | 1.14% | 3,460,000 +710,000 | +26% | +$16.3M |
|
|
17
Freshpet
FRPT
$2.72B
| $78.6M | 1.13% | 1,187,000 -949,000 | -44% | -$62.8M |
|
18
Alkermes
ALKS
$4.78B
| $76.8M | 1.11% | 2,724,000 -176,000 | -6% | -$4.96M |
|
19
Organon & Co
OGN
$2.45B
| $75.3M | 1.08% | 3,200,000 +800,000 | +33% | +$18.8M |
|
|
20
Colgate-Palmolive
CL
$67.9B
| $71.1M | 1.02% | 946,000 +845,000 | +837% | +$63.5M |
|
|
21
Johnson & Johnson
JNJ
$427B
| $71M | 1.02% | 457,883 +397,883 | +663% | +$61.7M |
|
22
Vertex Pharmaceuticals
VRTX
$100B
| $69.3M | 1% | 220,000 +72,000 | +49% | +$22.7M |
|
23
Madrigal Pharmaceuticals
MDGL
$9.76B
| $66.9M | 0.96% | 276,000 +68,000 | +33% | +$16.5M |
|
|
DCPH
24
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $63.3M | 0.91% | 4,100,000 -1,072,000 | -21% | -$16.6M |
|
25
Microsoft
MSFT
$3.77T
| $58.4M | 0.84% | 202,676 -21,324 | -10% | -$6.15M |
|